Phenotypic screens targeting neurodegenerative diseases.

Area of Science:

• Neuroscience
• Pharmacology
• Drug Discovery

Background:

• Neurodegenerative diseases impact millions globally, with increasing incidence in aging populations.
• Current disease-modifying therapies are lacking, representing a significant unmet medical need.
• Traditional target-based drug discovery has yielded limited success due to incomplete understanding of neurodegeneration mechanisms.

Purpose of the Study:

• To review the progress of compound screening using phenotypic-based strategies for neurodegenerative diseases.
• To highlight unique considerations for disease models, assays, and screening methodologies in phenotypic screening.
• To provide perspectives on utilizing phenotypic screening for developing drug leads.

Main Methods:

• Phenotypic screening identifies compounds modulating disease phenotypes rather than specific molecular targets.
• Strategies include ameliorating disease-specific toxins, protecting neurons, and promoting neuroregeneration.
• Review of existing literature and methodologies in phenotypic screening for neurodegeneration.

Main Results:

• Phenotypic screening presents a viable alternative to target-based discovery for neurodegenerative diseases.
• Successful phenotypic screens require careful selection of disease models, assays, and screening methodologies.
• This approach can uncover novel small molecules and therapeutic targets.

Conclusions:

• Phenotypic screening is a valuable strategy for identifying novel therapeutic agents for neurodegenerative diseases.
• Optimizing disease models and assays is crucial for effective phenotypic screening.
• Further research and application of phenotypic screening can advance drug development for these conditions.